City

Beijing (1)

Boston (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Phase

phase 1 (2)

early phase 1 (1)

Sponsor

Affiliated Hospital to Academy of Military Medical Sciences (1)

Dana-Farber Cancer Institute (1)

Kura Oncology, Inc. (1)

Collaborator

Beijing JD Biotech Co. LTD. (1)

The Leukemia and Lymphoma Society (1)

Intervention

venetoclax (2)

azacitidine (1)

cd123-car-nk cells (1)

cytarabine (1)

cytokine-induced memory-like natural killer cells (1)

daunorubicin (1)

interleukin-2 (1)

ziftomenib (1)

Study Documents

Intervention Type

biological (2)

drug (2)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

acute myeloid leukemia recurrent

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting

Acute Myeloid Leukemia
+3 more

Cytokine-Induced Memory-like Natural Killer Cells
+2 more

Boston, Massachusetts
+1 more

Nov 22, 2023

Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,

Not yet recruiting

Acute Myeloid Leukemia
+10 more

Ziftomenib
+4 more

(no location specified)

Feb 17, 2023

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)

Recruiting

Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia Recurrent

CD123-CAR-NK cells

Beijing, Beijing, China

The Fifth Medical Center of Chinese People's Liberation Army (PL

Oct 24, 2022